Sidley Advises Huma on Its Acquisition of AstraZeneca’s Digital Health Platform, AMAZE™️

Sidley advised Huma Therapeutics, a global digital health technology company, on its acquisition of AstraZeneca’s chronic disease management platform, AMAZE™️. As part of the transaction, Huma and AstraZeneca will enter into a collaboration agreement, and AstraZeneca shall also become a shareholder of Huma.

The Sidley team, based in London and Chicago, was led by partner Tom Thesing and managing associates Will Schoenfeld and Dan Stafford, with support from associate Zahira Butt (M&A and Private Equity). Additional support was provided by Suresh Advani, Oliver Currall, Pranith Mehta and Andrew Dibden (Tax); Kyle Barnett (Technology and Life Sciences Transactions); and Helen Middleton and Zina Chatzidimitriadou (Food, Drug and Medical Device Regulatory).